Tadayuki Oshima1, Liping Wu2,3, Min Li2,3, Hirokazu Fukui2, Jiro Watari2, Hiroto Miwa2. 1. Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. t-oshima@hyo-med.ac.jp. 2. Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. 3. Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu, China.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is a cause of increased morbidity and health care costs among hospitalized patients. Proton pump inhibitors (PPIs) are mainly used for the treatment of acid-related upper gastrointestinal diseases. The aim of the study was to assess the risks associated with initial and recurrent CDI in adult and pediatric patients treated with PPIs. METHODS: A systematic search was performed using PubMed (Medline), Embase, and Web of Science with the following search terms: ("proton pump inhibitor," "PPI," or "acid suppression") AND ("infection," "diarrhea," "diarrhoea," "colitis," or "disease") AND ("Clostridium difficile"). Meta-analysis was performed using Revman5.3 software. Pooled odds ratios (ORs) presented as standard plots with 95% confidence intervals (CIs) were determined. RESULTS: Sixty-seven eligible studies were selected. PPI use was significantly associated with risk of CDI (OR 2.34, 95% CI 1.94-2.82; P < 0.00001). Pooled data from twelve studies demonstrated a significant association between PPI use and recurrent CDI (OR 1.73, 95% CI 1.39-2.15; P = 0.02). Subgroup analysis revealed significant associations between PPI use and an increased incidence of CDI among adult (OR 2.30, 95% CI 1.89-2.80; P < 0.00001) and pediatric (OR 3.00, 95% CI 1.44-6.23; P < 0.00001) patients. CONCLUSIONS: PPI use was associated with CDI in adult and pediatric patients, and with recurrent CDI. Although many risk factors are associated with the occurrence and recurrence of CDI, consideration should be given to not administering PPIs at any age if they are unnecessary.
BACKGROUND:Clostridium difficileinfection (CDI) is a cause of increased morbidity and health care costs among hospitalized patients. Proton pump inhibitors (PPIs) are mainly used for the treatment of acid-related upper gastrointestinal diseases. The aim of the study was to assess the risks associated with initial and recurrent CDI in adult and pediatric patients treated with PPIs. METHODS: A systematic search was performed using PubMed (Medline), Embase, and Web of Science with the following search terms: ("proton pump inhibitor," "PPI," or "acid suppression") AND ("infection," "diarrhea," "diarrhoea," "colitis," or "disease") AND ("Clostridium difficile"). Meta-analysis was performed using Revman5.3 software. Pooled odds ratios (ORs) presented as standard plots with 95% confidence intervals (CIs) were determined. RESULTS: Sixty-seven eligible studies were selected. PPI use was significantly associated with risk of CDI (OR 2.34, 95% CI 1.94-2.82; P < 0.00001). Pooled data from twelve studies demonstrated a significant association between PPI use and recurrent CDI (OR 1.73, 95% CI 1.39-2.15; P = 0.02). Subgroup analysis revealed significant associations between PPI use and an increased incidence of CDI among adult (OR 2.30, 95% CI 1.89-2.80; P < 0.00001) and pediatric (OR 3.00, 95% CI 1.44-6.23; P < 0.00001) patients. CONCLUSIONS: PPI use was associated with CDI in adult and pediatric patients, and with recurrent CDI. Although many risk factors are associated with the occurrence and recurrence of CDI, consideration should be given to not administering PPIs at any age if they are unnecessary.
Authors: Amee R Manges; Aurelie Labbe; Vivian G Loo; Juli K Atherton; Marcel A Behr; Luke Masson; Patricia A Tellis; Roland Brousseau Journal: J Infect Dis Date: 2010-11-04 Impact factor: 5.226
Authors: I Vesteinsdottir; S Gudlaugsdottir; R Einarsdottir; E Kalaitzakis; O Sigurdardottir; E S Bjornsson Journal: Eur J Clin Microbiol Infect Dis Date: 2012-03-23 Impact factor: 3.267
Authors: Abhishek Deshpande; Vinay Pasupuleti; Priyaleela Thota; Chaitanya Pant; David D K Rolston; Adrian V Hernandez; Curtis J Donskey; Thomas G Fraser Journal: Infect Control Hosp Epidemiol Date: 2015-01-28 Impact factor: 3.254
Authors: Carlene A Muto; Marian Pokrywka; Kathleen Shutt; Aaron B Mendelsohn; Kathy Nouri; Kathy Posey; Terri Roberts; Karen Croyle; Sharon Krystofiak; Sujata Patel-Brown; A William Pasculle; David L Paterson; Melissa Saul; Lee H Harrison Journal: Infect Control Hosp Epidemiol Date: 2005-03 Impact factor: 3.254
Authors: R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon Journal: Br Med J Date: 1978-03-18
Authors: Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 10.864